ARNA Arena Pharmaceuticals Inc.

49.5
-0.42  -1%
Previous Close 49.92
Open 49.91
Price To Book 4.61
Market Cap 2445619374
Shares 49,406,452
Volume 146,411
Short Ratio
Av. Daily Volume 503,678

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data due 2019.
Etrasimod
Primary biliary cholangitis (PBC)
Phase 2 trial initiated March 2017.
Etrasimod
Pyoderma gangrenosum (PG)
Phase 2 trial initiated March 2017.
Etrasimod
Dermatological extraintestinal manifestations (EIM) in patients with inflammatory bowel disease (IBD)
Approved June 27, 2012.
Lorcaserin
Obesity
Phase 2/3 trial to be initiated 2019.
Olorinab (APD371)
Pain associated with Crohn's disease
Phase 2 initiated March 2014. Data released Nov 2014
Lorcaserin
Smoking cessation
Phase 3 trial to be initiated 2019.
Etrasimod
Ulcerative colitis
Phase 3 ongoing. Licensed to UTHR November 15, 2018.
Ralinepag
Pulmonary Arterial Hypertension
Phase 2 trial to be initiated 2019.
Etrasimod
Atopic dermatitis (AD)

Latest News

  1. Top 3 Marijuana Stocks on the NASDAQ
  2. Arena Pharmaceuticals Presents Preclinical and Early Clinical Development Data for Olorinab at Crohn's & Colitis Congress
  3. Is Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) A Financially Strong Company?
  4. Research Report Identifies Cameco, American Equity Investment Life Holding, AG Mortgage Investment Trust, Arena Pharmaceuticals, Mimecast, and Aldeyra Therapeutics with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
  5. The Daily Biotech Pulse: Intuitive Surgical Earnings, Corbus To Offer Shares, Eton In-Licenses Neurologic Drug
  6. United Therapeutics Announces Closing Of License Agreement With Arena Pharmaceuticals For Ralinepag
  7. Arena Pharmaceuticals Announces Closing of Global License Agreement with United Therapeutics for Ralinepag
  8. Today's Research Reports on Trending Tickers: Arena Pharmaceuticals and ACADIA Pharmaceuticals
  9. Arena Pharmaceuticals Reports Positive Long-Term Data from the Open-Label Extension of the Phase 2 OASIS Trial Evaluating Etrasimod for Treatment of Ulcerative Colitis
  10. Arena Pharmaceuticals to Present at the 37th Annual J.P. Morgan Healthcare Conference on January 10
  11. Arena Pharmaceuticals Appoints Experienced Life Sciences Industry Finance Executive Manmeet S. Soni to Board of Directors
  12. Is Arena Pharmaceuticals, Inc. (ARNA) A Good Stock To Buy?
  13. Today's Research Reports on Trending Tickers: Arena Pharmaceuticals and China Biologic Products Holdings
  14. What Did Arena Pharmaceuticals Inc’s (NASDAQ:ARNA) CEO Take Home Last Year?
  15. Today's Research Reports on Trending Tickers: Arena Pharmaceuticals and Sarepta Therapeutics
  16. Research Report Identifies Cheniere Energy Partners, LP, Arena Pharmaceuticals, Geron, Keysight Technologies, Grupo Aeroportuario del Centro Norte S.A.B. de C.V, and Casella Waste with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
  17. Analysts: Why United Therapeutics has had a streak of licensing deals
  18. A Look at Amarin Corporation’s Stock Performance Year-to-Date
  19. Arena Pharmaceuticals Expands Senior Management Team to Support Commercialization and Medical Affairs